{"product_id":"biolegend-100323","title":"Biolegend, 100323, Alexa Fluor® 488 anti-mouse CD3ε Antibody, 25μg","description":"\u003cp\u003eCD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with the CD3δ, γ and ζ chains, as well as the TCR α\/β or γ\/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide\/MHC antigen complex.\u003cbr\u003e\n25μg\u003cbr\u003e\nVerified Reactivity: Mouse\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Armenian Hamster\u003cbr\u003e\nImmunogen: H-2Kb-specific mouse cytotoxic T lymphocyte clone BM10-37\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography and conjugated with Alexa Fluor® 488 under optimal conditions.\u003cbr\u003e\nConcentration: 0.5 mg\/ml\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: FC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 2.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. * Alexa Fluor® 488 has a maximum emission of 519 nm when it is excited at 488 nm. Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.View full statement regarding label licenses\u003cbr\u003e\nExcitation Laser: Blue Laser (488 nm)\u003cbr\u003e\nApplication Notes: Clone 145-2C11 is useful for in vitro blocking of target-specific CTL-mediated cell lysis1, as well as T cell activation assays, inducing proliferation and cytokine production1,2,7,12,16. It also induces apoptosis in immature thymocytes32, and in vivo T cell depletion8-10. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1, immunohistochemical staining14,15 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting4, complement-mediated cytotoxicity6, in vitro and in vivo stimulation of T cells1,2,7,12,16, immunofluorescent staining5, and in vivo T cell depletion8-10. The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells11. Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF™ purified antibody (Endotoxin \u0026lt;0.1 EU\/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100314). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin \u0026lt;0.01 EU\/µg).\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block) Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ) Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB) Payer E, et al. 1991. J. Immunol. 146:2536. (IF) Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD) Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ) Henrickson M, et al. 1995. Transplantation 60:828. (Deplete) Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete) Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete) Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block) Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ) Ko SY, et al. 2005. J. Immunol. 175:3309. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F) Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F) Wang W, et al. 2007. J. Immunol. 178:4885. (Activ) Xiao S, et al. 2007. J. Exp. Med. 204:1691. Chappaz S, et al. 2007. Blood doi:10.1182\/blood-2007-02-074245. (FC) PubMed. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed Guo Y, et al. 2008. Blood 112:480. PubMed Kenna TJ, et al. 2008. Blood 111:2091. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed Schulteis RD, et al. 2008. Blood 295:G273. PubMed Qi Q, et al. 2009. Blood 114:564. PubMed Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed Yan J, et al. 2014. Vaccine. 32:2833. PubMed Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)\u003cbr\u003e\nProduct Citations: Whyte CE, et al. 2022. Curr Protoc. 2:e589. PubMed Ajith A, et al. 2021. Front Immunol. 12:687715. PubMed Shigematsu Y, et al. 2013. Cancer Lett . 340:141. PubMed Bhattacharya Y 2014. J Exp Med. 211:841. PubMed Mogilenko DA, et al. 2020. Immunity. 54(1):99-115.e12. PubMed Baranek T, et al. 2020. Cell Reports. 32(10):108116. PubMed del Rio ML, et al. 2021. Transl Res. Online ahead of print.. PubMed Onishi S, et al. 2015. PLoS One. 10:126564. PubMed Tian D, et al. 2020. FASEB J. 34:3367. PubMed He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed Chen C, et al. 2019. Cell Rep. 29:4200. PubMed Tuganbaev T, et al. 2020. Cell. 182(6):1441-1459.e21. PubMed Bambouskova M, et al. 2021. Cell Reports. 34(10):108756. PubMed Sido J, et al. 2015. J Leukoc Biol. 98: 435-447. PubMed Oka Y, et al. 2020. Sci Adv. 6:. PubMed Korrer M, Routes J 2014. PLoS One. 9:91370. PubMed Hu M, et al. 2020. Cancer Immunol Res. 8:1150. PubMed de Picciotto S, et al. 2022. Nat Commun. 13:3866. PubMed Miyajima M,et al. 2017. Nat Immunol.. 10.1038\/ni.3867. PubMed Wu R, et al. 2020. J Immunother Cancer. 8:00. PubMed Ajith A, et al. 2019. FASEB J. 33:5220. PubMed Uotila LM, et al. 2017. J Immunol. 199:3644. PubMed\u003cbr\u003e\nRRID: AB_389300 (BioLegend Cat. No. 100321)\u003cbr\u003e\nStructure: Ig superfamily, forms CD3\/TCR complex with CD3δ, γ and ζ subunits and TCR (α\/β and γ\/δ), 20 kD\u003cbr\u003e\nDistribution: Thymocytes (differentiation dependent), mature T cells, NK-T cells\u003cbr\u003e\nFunction: TCR signal transduction, T cell activation, antigen recognition\u003cbr\u003e\nLigand\/Receptor: Peptide antigen\/MHC-complex\u003cbr\u003e\nCell Type: NKT cells, T cells, Thymocytes, Tregs\u003cbr\u003e\nBiology Area: Immunology\u003cbr\u003e\nMolecular Family: CD Molecules, TCRs\u003cbr\u003e\nAntigen References: 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Davis MM. 1990. Annu. Rev. Biochem. 59:475. 3. Weiss A, et al. 1994. Cell 76:263.\u003cbr\u003e\nGene ID: 12501\u003cbr\u003e\nUniProt: View information about CD3epsilon on UniProt.org\u003cbr\u003e\nClone: 145-2C11\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: CD3ε, T3, CD3\u003cbr\u003e\nIsotype: Armenian Hamster IgG\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46860803801257,"sku":"100323","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/ar\/products\/biolegend-100323","provider":"Iright","version":"1.0","type":"link"}